1stOncology™: Cancer Intelligence Service – Page 9866 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Leidos To Participate In The J.P. Morgan 2021 Virtual Industrials Conference

On March 9, 2021 Leidos (NYSE: LDOS), a FORTUNE 500 science and technology company, reported that it will participate in the J.P. Morgan 2021 Virtual Industrials Conference webcast (Press release, Leidos, MAR 9, 2021, View Source [SID1234576315]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Roger Krone, Chief Executive Officer, will participate in a question and answer "fireside chat" on Tuesday, March 16, 2021 at 3:40 p.m. ET.

A live audio webcast of the event will be available on the Leidos Investor Relations website at View Source A replay of the webcast will be available following the presentation at the same link listed above for 30 days afterward.

Labcorp Named to Fast Company’s List of the World’s Most Innovative Companies for 2021

On March 9, 2021 Labcorp (NYSE: LH), a leading global life sciences company, reported that it has been named to Fast Company magazine’s list of 2021 Most Innovative Companies. Since 2008, the annual list has been the definitive source for recognizing the organizations that are transforming industries and shaping society (Press release, LabCorp, MAR 9, 2021, https://ir.labcorp.com/news-releases/news-release-details/labcorp-named-fast-companys-list-worlds-most-innovative [SID1234576314]).

Labcorp was cited for its leadership in science, innovation, and healthcare in the fight against COVID-19 by advancing testing, partnering with biopharmaceutical companies to accelerate the launch of new treatments and vaccines, and providing vital support services so people could return to work and to life activities. In addition to Labcorp’s response to COVID-19, the company provides diagnostic testing and drug development services for patients, doctors, researchers, and hospital systems across therapeutic areas including cancer, Alzheimer’s disease, autoimmune disorders, kidney and liver diseases, diabetes, and other conditions.

"The recognition by Fast Company is a testament to our leadership in science and the commitment of our global employees to improve health and improve lives," said Adam Schechter, chairman and CEO, Labcorp. "Our innovations in testing, clinical trial delivery, technology, and insights have enabled us to deliver trusted, timely information to physicians, biopharmaceutical companies, and patients, so they can make clear and confident decisions."

Labcorp brought a number of innovations to market in the last year:

Labcorp was the first company to receive an FDA Emergency Use Authorization to launch several COVID-19 PCR tests, including the Pixel by LabcorpⓇ COVID-19 PCR Test Home Collection Kit now available through retail, and helped bring multiple treatments and vaccines to market in record time. The company’s science and technology are also being leveraged to genetically sequence thousands of samples each week to identify variants that can inform future vaccines and treatments.
Using robotics, Labcorp increased COVID-19 testing capacity and developed proprietary insight and analytics capabilities to help clients improve their operations, guide patient care, and support clinical trials across a larger number of programs and therapeutic areas.
The company is improving the efficiency of clinical trials through the use of mobile and digital technologies to make decentralized and virtual clinical trials a reality.
Labcorp performed over 40 million COVID-19 tests in the last year, more than any other U.S. commercial lab, and broadened access to COVID-19 testing for millions of people through hospitals, retail, employers, physicians, drive-through sites, and its Pixel by Labcorp COVID-19 PCR Test Home Collection Kit.
The 2021 Most Innovative Companies list can be found on Fast Company’s website. Fast Company’s editors and writers sought out the most groundbreaking businesses around the globe in all industries. They also judged nominations received through their application process.

"In a year of unprecedented challenges, the companies on this list exhibit fearlessness, ingenuity and creativity in the face of crisis," said Fast Company Deputy Editor David Lidsky, who oversaw the issue with Senior Editor Amy Farley.

Jounce Therapeutics Announces Proposed Offering of Common Stock

On March 9, 2021 Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported that it is offering to sell shares of its common stock in an underwritten public offering (Press release, Jounce Therapeutics, MAR 9, 2021, View Source [SID1234576313]).

The proceeds of the offering are expected to be used to fund ongoing and planned clinical trials, including the INNATE trial for JTX-8064, to fund research and development to advance Jounce’s pipeline, and for working capital and other general corporate purposes. All of the shares in the offering are to be sold by Jounce. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Jounce also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the offering on the same terms and conditions.

Cowen and Piper Sandler are acting as joint book-running managers for the offering.

The proposed offering is being made pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission ("SEC") on March 8, 2018 and declared effective by the SEC on May 1, 2018. The offering will be made only by means of the prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to, and describing the terms of, the offering will be filed with the SEC and will be available on the SEC’s web site at www.sec.gov.

Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering can be obtained from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by telephone at 833-297-2926; or from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

GeneCentric Therapeutics Announces New US Patent Granted for Molecular Characterization of Non-Squamous Non-Small Cell Lung Cancer

On March 9, 2021 GeneCentric Therapeutics, a company making precision medicine more precise, reported the granting of Patent No. 10,934,595 by the United States Patent and Trademark Office (USPTO), protecting another one of its novel RNA-based lung cancer gene signatures (Press release, GeneCentric Therapeutics, MAR 9, 2021, View Source [SID1234576311]). This new patent provides further demonstration of the novel RNA-based technology achievements of the GeneCentric team and its growing pipeline of predictive response signatures developed using its Tumor and Immune Micro-Environment (T(I)ME) Explorer platform.

The patent covers the use of reduced RNA gene sets to characterize tumors from patients diagnosed with non-squamous non-small cell lung cancer (NSCLC), which are foundational to the development of the company’s predictive response signatures and diagnostics for this important patient population. The use of RNA-based gene signatures allows for a deeper understanding of the T(I)ME than DNA mutations alone, often allowing for the identification of a broader patient population that may benefit from targeted therapy compared to use of traditional DNA mutation analysis.

"Those of us who study the genomics of lung cancer have known for more than a decade that there is a rich and reproducible story to be told though gene expression assays," said Neil Hayes, MD, GeneCentric co-founder, and Scientific Director, University of Tennessee West Institute for Cancer Research. "The signatures inherent to clinically relevant subgroups are opaque to the microscope but revealed through the genome. We are thrilled to open the door to applications applicable to prognosis and response for traditional cytotoxic chemotherapy, targeted therapies, and emerging immune-oncologic approaches."

GeneCentric continues to make significant progress with its growing pipeline of RNA-based predictive response signatures and molecular diagnostics, with the lung cancer program as its cornerstone. Further updates will be provided as the company presents additional data validating its novel RNA-based signatures and diagnostic tests across multiple tumor types at upcoming scientific meetings and in peer-reviewed publications.

"This is an important time for GeneCentric as we clinically validate and prepare to launch this diagnostic test," said Dr. Mike Milburn, President, and CEO of GeneCentric Therapeutics. "The granting of this latest lung cancer patent by the USPTO demonstrates the utility and uniqueness of our growing pipeline of RNA-based diagnostics,"

Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call

On March 9, 2021 Five Prime Therapeutics, Inc. (NASDAQ: FPRX) reported that it has canceled its fourth quarter and full year 2020 earnings conference call, which was previously scheduled for Wednesday, March 10, 2021 at 1:30 p.m. PT / 4:30 p.m. ET (Press release, Five Prime Therapeutics, MAR 9, 2021, View Source [SID1234576310]).

The cancellation is the result of the company’s announcement on March 4, 2021 that it has entered into an agreement under which Amgen Inc. will acquire Five Prime Therapeutics. Five Prime will issue its fourth quarter and full-year 2020 financial results in its Form 10-K that it will file with the Securities and Exchange Commission.